Compare AbCellera Biologics Inc (ABCL) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs SoFi Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while SoFi Technologies Inc trades at $17.48 (market cap $22.77B). The key difference: SoFi Technologies Inc is far larger — about 9.7× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SOFI | |
|---|---|---|
Market Cap | $2.35B | $22.77B |
Sector | Health | Financials |
52-Week High | $8.12 | $32.21 |
52-Week Low | $2.78 | $15.15 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SOFI stock trades at $17.75, down 2.69% on the day, with a bullish technical signal and strong support at $17. The company reported revenue growth to $3.61B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion into small business loans and AI-driven products like Coach and Composer, aiming to deepen member engagement.
Outlook remains positive with a consensus price target of $21.22, offering 20% upside potential. Key risks include negative operating cash flow and high valuation multiples. Growth catalysts are centered on loan originations and ecosystem expansion, but investors should monitor execution and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
